Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK1R | ISIN: KYG4987A1094 | Ticker-Symbol: 77V
Stuttgart
15.05.25 | 08:02
0,474 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,4800,53022:54
0,4800,53021:41

Aktuelle News zur JACOBIO PHARMACEUTICALS GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJACOBIO-B (01167): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING2
JACOBIO PHARMACEUTICALS GROUP Aktie jetzt für 0€ handeln
MiJACOBIO-B (01167): NOTICE OF 2025 ANNUAL GENERAL MEETING-
MiJACOBIO-B (01167): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED AMENDMENTS ...-
FrJACOBIO-B (01167): PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ...1
FrJACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT SHP2 INHIBITOR SITNEPROTAFIB COMBINATION THERAPY DATA PUBLISHED IN ACADEMIC JOURNAL1
30.04.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT CHANGES IN THE INTERESTS OF THE PARTIES ACTING IN CONCERT-
25.04.JACOBIO-B (01167): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS3
25.04.JACOBIO-B (01167): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
24.04.JACOBIO-B (01167): 2024 ANNUAL REPORT3
16.04.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN1
19.03.Jacobio Pharma Announces 2024 Annual Results240BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense...
► Artikel lesen
19.03.JACOBIO-B (01167): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
19.03.JACOBIO-B (01167): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; CHANGE IN USE OF PROCEEDS; AND CHANGE IN THE COMPOSITION OF THE NOMINATION ...1
07.03.JACOBIO-B (01167): DATE OF BOARD MEETING-
06.01.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL CLINICAL DATA OF KRAS INHIBITOR GLECIRASIB WAS PUBLISHED IN THE MEDICAL JOURNAL NATURE MEDICINE1
09.12.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRELIMINARY CLINICAL DATA OF BET INHIBITOR JAB-8263 TO TREAT MYELOFIBROSIS AT THE 2024 ...-
25.11.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE I/IIA CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN ...1
25.06.24XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.06.2024687The following instruments on XETRA do have their first trading 25.06.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.06.2024 Aktien 1 US76657Y1010 Rightmove PLC ADR 2...
► Artikel lesen
02.06.24Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO269BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1